| Ticker |
CMRX
|
| CIK | 0001117480 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713 |
| Website | chimerix.com |
| Phone | 919.806.1074 |
| CEO | Michael A. Sherman |
| Employees | 90 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Is Chimerix Inc. (CMRX) the Best Performing NASDAQ Stock So Far in 2025?We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against other best performing NASDAQ stocks so far in 2025. On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s ‘Closing […] Exploring US High Growth Tech Stocks In March 2025In the United States, the market has experienced a 3.5% decline over the last week, yet it remains up by 5.8% over the past year with earnings expected to grow annually by 14%. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability in response to evolving market dynamics. Chimerix Inc. (NASDAQ:CMRX) Amazing Performance So Far In 2025We recently published a list of the 11 Best Performing Stocks So Far In 2025. In this article, we are going to take a look at where Chimerix Inc. (NASDAQ:CMRX) stands against the other best performing stocks so far in 2025. On March 21, Jason Pride, Chief of Investment Strategy at Glenmede, and Stephen DeNichilo, […] Chimerix: Q4 Earnings SnapshotThe Durham, North Carolina-based company said it had a loss of 25 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share. Chimerix Reports Fourth Quarter and Year End 2024 Financial ResultsNew Drug Application (NDA) for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Under Review with Prescription Drug User Fee Act (PDUFA) Action Date of August 18, 2025 Acquisition of Chimerix by Jazz Pharmaceuticals (Jazz) Expected to Close in Second Quarter of 2025 DURHAM, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing dea |
